The positive results from the TRANSCEND CLL 004 Phase 1/2 study of Breyanzi and the Phase 3 COMMANDS study of Reblozyl indicate potential for increased demand and revenue for Bristol Myers Squibb. The statistically significant complete response rates and high rates of undetectable minimal residual disease for Breyanzi, as well as the efficacy of Reblozyl in treating anemia in adult patients with myelodysplastic syndromes, suggest that these products may become important treatment options in their respective markets. This could lead to increased revenue for the company and a positive impact on its stock price in the short term.